E-Articles - Finance

Where do you stand at the end of the third quarter 2005? Will you be making money in your account this year? There’s only one quarter of 2005 left! The ov

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

erall market averages have not done well at all! At first glance, it appears that if you own large cap growth stocks, like the well known blue chip names th

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

at dominate the Dow and the S&P 500 Index, your money may have been better off on the sidelines! Once again, another quarter has rolled by where small caps,

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

foreign markets, technology and commodities have run the table. And these sectors continue to flash more and more buy signals, even today. It’s not too lat

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

e! This is a sector driven market. Those investors with money in the right sectors will do well. Those that are “along for the ride” will find themselves

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

aiting at the curb.

Staying Safe In A High Risk Market

There are MANY paths you can take when things start moving against you in the market. Some of the ot

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

her methods involve selling calls against your individual stocks, buying inverse market funds and inverse index funds. You can also move into other types of

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

investments, like foreign markets and commodities (as mentioned earlier, both of these areas have skyrocketed this year). You could always put money in bon

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

s, if interest rates are in your favor. Just keep in mind that bond prices go up and down, so you will always have your principal fluctuating in bond invest

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

ments. Always. One of the very simplest, and yet, one of the most important steps you can take is to do a little housecleaning. Throw out the stocks that

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

ust don’t seem to fit, or offer little hope of coming back any time soon.

Looking Backwards

Periodically, I’ll review a position backwards. That is, I wil

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

l check out the trend chart and its patterns, the strength of the sector, check out the relative strength of the stock against the market and the peer group.

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

At that point I will step back and decide if this is something I would want to buy today. Not hold onto, but rather, buy today. You have to really love i

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

.

Once I’ve made a decision whether I’m a buyer, only then will I look at the NAME of the stock.

Try it; you may be surprised with your decisions! You see

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

, many times we look at the name of a stock we really like and we are pre-disposed to give it a “pass” if it is not performing. Sometimes, our sub-conscious

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

has already made up its mind before step one!

Now, if you’d like to try this experiment on your own holdings, then email me at tom@mullooly.net and give me

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

the names a few stocks you are concerned about. It has to be more than one stock, I need to mix them up and remove the names, so you can’t tell which chart

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

I’m sending you first. As I mentioned before, the results may surprise you!

One strategy you won't see from us when we’re in a high risk market is doing no

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

hing, and just "sitting out this dance.” You've worked too hard to get where you are financially, the last thing you should do is sit idle and let the marke

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

t take your profits away from you.

Reducing the chances of a loss in your account is what should be of supreme importance when the market is on shaky ground

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.e-article.org.ua/article/104331/e-article-Staying-Safe-In-A-High-Risk-Market.html">Staying Safe In A High Risk Market</a>

BB link (for phorums):
[url=http://www.e-article.org.ua/article/104331/e-article-Staying-Safe-In-A-High-Risk-Market.html]Staying Safe In A High Risk Market[/url]

Learn how proper document localization can improve your globalization process. See what the pros are doing.

Increase your productivity and watch your profits soar when you implement a simple productivity plan!

Small businesses are thriving to find a new way to improve their competitive edge every day. These days, internet comes not only for the aid of big corporations but small business too can benefit from this amazing technology.

Tags

Links

E-Articles - Staying Safe In A High Risk Market

Related Articles: